<DOC>
	<DOC>NCT02089269</DOC>
	<brief_summary>The registry aims to collect and analyse information on the antineoplastic treatment of metastatic or locally advanced pancreatic cancer in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.</brief_summary>
	<brief_title>Tumor Registry Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Metastatic or locally advanced pancreatic cancer 18 years and older Antineoplastic treatment Date of consent no later than 2 weeks after start of firstline treatment No pancreatic cancer Below 18 years and older No antineoplastic treatment Date of consent later than 2 weeks after start of firstline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pancreatic neoplasms</keyword>
	<keyword>neoplasms</keyword>
	<keyword>registry</keyword>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>health services research</keyword>
	<keyword>epidemiology</keyword>
	<keyword>Germany</keyword>
	<keyword>palliative treatment</keyword>
	<keyword>palliative care</keyword>
</DOC>